GO:0006747 FAD biosynthetic process: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006747 (FAD biosynthetic process) describes the chemical reactions and pathways that build FAD, the oxidized form of flavin adenine dinucleotide.
• FAD is the redox-active cofactor of hundreds of human flavoproteins, so its biosynthesis underpins mitochondrial energy metabolism, fatty acid oxidation, redox homeostasis and one-carbon metabolism.
• The pathway converts riboflavin (vitamin B2) through FMN to FAD, and its output controls the stability and activity of downstream flavoproteins such as FSP1.
• FAD availability is now recognized as an immunometabolic signal: the microbial metabolite FAD remodels adipocyte lipid handling and enhances cancer immunotherapy efficacy.
• Flavoprotein and flavin-dependent enzymes are structurally and allosterically tuned, as shown for acyl-CoA oxidase, whose activity is regulated by ATP.
• CRISPR knockout, point-mutation, knock-in and overexpression models allow causal testing of FAD biosynthetic genes in cancer, ferroptosis and neurodegeneration research.
Description
FAD biosynthetic process (GO:0006747) is the biological process that produces flavin adenine dinucleotide in its oxidized form, the principal redox cofactor used by flavoenzymes across all kingdoms of life. The term covers the enzymatic steps that convert the vitamin B2 precursor riboflavin into FMN and then into FAD, as well as the metabolic context that supplies the required substrates and cofactors. Because FAD is the oxidized form of the dinucleotide, the process is intimately linked to cellular redox balance and to the activity of flavoprotein families that include oxidoreductases, dehydrogenases and electron-transfer proteins. For researchers, GO:0006747 matters because FAD is not merely a static cofactor but a dynamic metabolic node. The human flavoproteome comprises a large set of FAD- and FMN-dependent proteins whose functions depend on adequate FAD biosynthesis. Recent work shows that vitamin B2 metabolism promotes the stability of FSP1, a glutathione-independent ferroptosis suppressor, directly connecting FAD biosynthesis to cell-death control. In parallel, the microbial metabolite FAD has been shown to mobilize adipocyte lipid remodeling and enhance cancer immunotherapy efficacy, indicating that FAD levels can act as inter-organismal signals. Mechanistic studies of flavoenzymes further reveal how FAD-dependent catalysis is tuned by substrate and nucleotide binding, as illustrated by ATP allosteric regulation of an acyl-CoA oxidase. Together, these findings position GO:0006747 as a convergence point for metabolism, redox biology, immunology and disease, making it a compelling target for CRISPR-based functional genomics.
FAD biosynthetic process At A Glance
| GO ID | GO:0006747 |
|---|---|
| GO term | FAD biosynthetic process |
| Ontology | biological_process |
| Definition | The chemical reactions and pathways resulting in the formation of FAD, the oxidized form of flavin-adenine dinucleotide. |
| Synonyms | FAD anabolism; FAD biosynthesis; FAD formation; FAD synthesis; oxidized flavin adenine dinucleotide biosynthesis; oxidized flavin-adenine dinucleotide biosynthetic process |
| Major function | Production of the FAD cofactor required by flavoproteins for redox catalysis and electron transfer |
| Key precursor | Riboflavin (vitamin B2), converted through FMN to FAD |
| Disease relevance | Ferroptosis suppression via FSP1 stability, cancer immunotherapy response, and flavoprotein-related metabolic disorders |
| Research methods | CRISPR knockout/knock-in, metabolomics, flavoproteome profiling, and biochemical enzyme assays |
What Is GO:0006747?
In plain terms, GO:0006747 describes the set of biochemical reactions that cells use to manufacture FAD, the oxidized form of flavin adenine dinucleotide. The process begins with riboflavin (vitamin B2) and proceeds through phosphorylation and adenylylation steps to yield FAD, which then serves as a tightly or non-covalently bound cofactor for flavoproteins. The QuickGO definition emphasizes that the term refers specifically to the formation of the oxidized dinucleotide, distinguishing it from the reduced forms and from FAD catabolism.
Why Is FAD biosynthetic process Important in Cell Biology?
FAD biosynthetic process is important because FAD is the indispensable cofactor for a large fraction of oxidative enzymes, and its availability sets the ceiling for mitochondrial fatty acid oxidation, amino acid catabolism, redox defense and one-carbon metabolism. Beyond housekeeping, FAD biosynthesis has emerged as a regulatory and signaling node: vitamin B2 metabolism stabilizes FSP1 to prevent ferroptosis, and the microbial metabolite FAD can remodel adipocyte lipid metabolism to enhance cancer immunotherapy efficacy. Consequently, perturbing GO:0006747 can reshape cell death thresholds, metabolic flux and immune-tumor interactions, making it a high-value process for mechanistic and translational research.
• Supplies FAD to hundreds of flavoproteins, including dehydrogenases and oxidoreductases central to energy metabolism.
• Controls ferroptosis sensitivity through FSP1 stability and vitamin B2 metabolism.
• Links microbial metabolism to host adipocyte lipid remodeling and immunotherapy efficacy.
• Provides the cofactor context for flavoenzyme allostery, as shown for ATP-regulated acyl-CoA oxidase.
• Relevant to cancer biology because FAD-dependent enzymes participate in redox and metabolic reprogramming.
• Relevant to neurodegeneration research, where metabolic and biomarker studies increasingly examine flavin-related pathways.
• Enables biochemical dissection of flavin-dependent catalysis using single-molecule and structural approaches.
• Supports synthetic biology and natural-product research, since flavin-dependent enzymes participate in complex biosynthetic transformations.
• Offers tractable CRISPR targets for knockout, point-mutation and knock-in studies of metabolic causality.
• Connects vitamin B2 status to cellular stress responses and cell-fate decisions.
What Happens During FAD biosynthetic process?
Riboflavin uptake and phosphorylation to FMN
In simple terms: The cell first takes in vitamin B2 and adds a phosphate group to it.
FAD biosynthesis begins with riboflavin (vitamin B2), which is phosphorylated to form flavin mononucleotide (FMN). This step is the entry point of the pathway and determines how much flavin precursor is available for downstream conversion to FAD. Because riboflavin is an essential vitamin, its uptake and phosphorylation are rate-limiting for the entire FAD biosynthetic process in many cell types.
Adenylylation of FMN to form FAD
In simple terms: A second module, AMP, is attached to FMN to make the full FAD molecule.
The terminal step of GO:0006747 converts FMN to FAD by transferring an adenylyl group from ATP, producing the oxidized flavin adenine dinucleotide. This reaction completes the dinucleotide structure that allows FAD to engage flavoprotein active sites and participate in one- and two-electron transfer reactions. The resulting FAD pool supports the human flavoproteome, which depends on FAD or FMN for catalytic activity.
Flavoprotein cofactor loading and redox function
In simple terms: Once FAD is made, it is inserted into enzymes that use it to move electrons.
Newly synthesized FAD is delivered to flavoproteins, where it serves as a tightly or non-covalently bound cofactor for redox catalysis. The functional output of FAD biosynthesis is therefore measured not only by FAD concentration but by the activity of FAD-dependent enzymes such as oxidoreductases and dehydrogenases. Structural and kinetic studies of flavoenzymes, including acyl-CoA oxidase, show that cofactor chemistry is coupled to substrate and nucleotide binding.
FAD as a metabolic and signaling output
In simple terms: FAD levels can act as signals that change how cells handle lipids and death signals.
Beyond its cofactor role, FAD produced through this pathway can influence cell fate and intercellular communication. Vitamin B2 metabolism promotes FSP1 stability to prevent ferroptosis, directly linking FAD biosynthesis to lipid peroxidation defense. In addition, the microbial metabolite FAD mobilizes adipocyte lipid remodeling and enhances cancer immunotherapy efficacy, showing that FAD can act as a host-microbe signal.
Flavin-dependent transformations in specialized biosynthesis
In simple terms: Some organisms use flavin chemistry to build complex natural products.
Flavin-dependent enzymes participate in specialized biosynthetic routes, including pyrroloiminoquinone biosynthesis, where unexpected transformations occur during construction of the final scaffold. These examples illustrate how FAD and related flavin cofactors enable oxidative chemistry beyond central metabolism. They also highlight the broader biochemical reach of flavin-dependent catalysis that depends on FAD biosynthetic process.
Key Genes Involved in GO:0006747 FAD biosynthetic process
The genes and proteins below are directly or functionally connected to FAD biosynthetic process (GO:0006747) and its downstream flavoprotein network, based on the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RFK | Riboflavin kinase that phosphorylates riboflavin to FMN | Entry step of FAD biosynthesis; target for metabolic flux studies |
| FLAD1 | FAD synthetase that adenylylates FMN to FAD | Terminal enzyme of GO:0006747; candidate for knockout and point-mutation studies |
| SLC52A1 | Riboflavin transporter supporting precursor uptake | Determines substrate availability for FAD biosynthesis |
| SLC52A2 | Riboflavin transporter supporting precursor uptake | Relevant to flavin-dependent metabolic and neurological phenotypes |
| SLC52A3 | Riboflavin transporter supporting precursor uptake | Links vitamin B2 status to FAD-dependent processes |
| FSP1 | Glutathione-independent ferroptosis suppressor stabilized by vitamin B2 metabolism | Direct downstream readout of FAD availability and ferroptosis control |
| ACOX1 | Peroxisomal acyl-CoA oxidase, a FAD-dependent enzyme | Model for ATP allosteric regulation of flavoenzymes |
| ETFA | Electron transfer flavoprotein subunit A | Mitochondrial flavoprotein dependent on FAD cofactor |
| ETFB | Electron transfer flavoprotein subunit B | Mitochondrial flavoprotein dependent on FAD cofactor |
| ETFDH | Electron transfer flavoprotein dehydrogenase | FAD-dependent enzyme in fatty acid oxidation |
| SDHA | Succinate dehydrogenase complex flavoprotein subunit A | TCA cycle flavoenzyme requiring FAD |
| SDHB | Succinate dehydrogenase complex flavoprotein subunit B | TCA cycle and respiratory chain flavoprotein |
| MTHFR | One-carbon metabolism enzyme with flavin-dependent regulation | Connects FAD status to folate and methylation pathways |
| DHODH | Dihydroorotate dehydrogenase, a FAD-dependent enzyme | Links FAD biosynthesis to pyrimidine synthesis |
| MAOB | Monoamine oxidase B, a FAD-dependent enzyme | Neurobiology and neurodegeneration relevance |
| PP2R5C | PPP2R5C regulatory subunit implicated in Alzheimer's disease biomarker studies | Illustrates metabolic and biomarker research adjacent to flavin biology |
| FMO3 | Flavin-containing monooxygenase 3 | Flavin-dependent oxidative metabolism |
How Is FAD biosynthetic process Regulated?
FAD biosynthetic process is regulated at multiple levels. Substrate supply through riboflavin transporters and the activity of riboflavin kinase and FAD synthetase determine the rate of FAD formation. Downstream, FAD availability controls the stability and function of flavoproteins such as FSP1, so changes in vitamin B2 metabolism can shift ferroptosis sensitivity. Flavin-dependent enzyme activity is also subject to allosteric control, as demonstrated for acyl-CoA oxidase, where ATP binding regulates catalysis. In addition, microbial production of FAD can act as an external signal that remodels host adipocyte lipid metabolism and influences immunotherapy efficacy.
FAD biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FSP1 | Ferroptosis suppression and cancer cell survival | FSP1 knockout and point-mutation cell lines with FAD supplementation |
| FLAD1 | FAD biosynthesis deficiency and metabolic stress | FLAD1 knockout with metabolomic rescue |
| ACOX1 | Peroxisomal fatty acid oxidation and allosteric regulation | ACOX1 knock-in of ATP-binding mutants |
| MAOB | Neurodegeneration and monoamine metabolism | MAOB knockout neuronal models |
| ETFDH | Mitochondrial fatty acid oxidation disorders | ETFDH knockout myoblasts and flux assays |
FAD biosynthesis and ferroptosis in cancer
Vitamin B2 metabolism promotes FSP1 stability to prevent ferroptosis, a lipid-peroxidation-driven form of cell death. Because FSP1 depends on the FAD pool generated through GO:0006747, perturbations in FAD biosynthesis can alter ferroptosis thresholds and influence tumor cell survival. This has direct implications for cancer therapy, where ferroptosis induction is an emerging strategy.
Microbial FAD and immunotherapy response
The microbial metabolite FAD mobilizes adipocyte lipid remodeling and enhances cancer immunotherapy efficacy. This finding positions FAD not only as an intracellular cofactor but also as a host-microbe signal that shapes systemic metabolism and anti-tumor immunity. It suggests that FAD biosynthetic process and FAD availability could be explored as biomarkers or modulators of immunotherapy response.
Flavoprotein dysfunction and metabolic disease
The human flavoproteome relies on FAD and FMN for catalytic activity, so defects in FAD biosynthesis can impair mitochondrial fatty acid oxidation, electron transfer and redox homeostasis. FAD-dependent enzymes such as acyl-CoA oxidase are also subject to allosteric regulation, meaning that metabolic signals can tune their output. These mechanisms connect GO:0006747 to inherited and acquired metabolic disorders.
Flavin biology in neurodegeneration research
Metabolic and biomarker studies in neurodegeneration increasingly examine flavin-related and metabolic pathways, as illustrated by work identifying PPP2R5C as a potential plasma biomarker for early Alzheimer's disease diagnosis. FAD-dependent enzymes such as monoamine oxidase B are also relevant to neurobiology. Together, these lines of evidence support further investigation of FAD biosynthetic process in neurodegenerative contexts.
From FAD biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is FLAD1 required for FAD production and flavoprotein activity? | FLAD1 knockout cell line with FAD metabolomics |
| Does a catalytic residue in FAD synthetase control flux? | Point-mutation knock-in of FLAD1 active-site variants |
| Can tagged FAD biosynthetic enzymes be localized? | Tagged knock-in of RFK or FLAD1 with fluorescent tags |
| Does FAD availability control ferroptosis? | FSP1 knockout and overexpression under vitamin B2 modulation |
| Does ATP binding tune flavoenzyme activity? | ACOX1 point-mutation knock-in and kinetic assays |
| Can FAD biosynthesis be studied at single-molecule resolution? | Single-molecule enzymatic assays on flavoenzymes |
How to Study the FAD biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Targeted metabolomics | Riboflavin, FMN and FAD levels | Quantifying flux through FAD biosynthesis |
| Enzyme activity assays | Flavoprotein catalytic rates | Assessing functional FAD availability |
| CRISPR knockout screens | Gene essentiality and pathway dependencies | Identifying FAD biosynthesis vulnerabilities |
| Single-molecule enzymology | Dynamic catalytic states | Resolving flavoenzyme mechanisms |
| Structural biology | Cofactor and substrate binding sites | Understanding flavoenzyme architecture |
| Lipid peroxidation assays | Ferroptosis sensitivity | Linking FAD to cell death |
| Immunometabolism assays | Adipocyte lipid remodeling and immune activation | Testing FAD as a host-microbe signal |
| Plasma biomarker profiling | Circulating metabolic and protein markers | Early diagnosis research in neurodegeneration |
Metabolomics and flavin profiling
Targeted metabolomics can quantify riboflavin, FMN and FAD to measure flux through GO:0006747. Such profiling is essential for linking genetic perturbations to cofactor pools and for interpreting flavoprotein phenotypes.
Flavoproteome and enzyme activity assays
Because FAD is the cofactor for a large flavoproteome, activity assays for dehydrogenases and oxidoreductases provide functional readouts of FAD biosynthesis. Kinetic studies of enzymes such as acyl-CoA oxidase reveal how substrate and nucleotide binding regulate catalysis.
Single-molecule and biophysical approaches
Single-molecule enzymatic dynamics can resolve heterogeneity and conformational cycling in flavin-dependent catalysis. These approaches complement structural and steady-state kinetic data on flavoenzymes.
CRISPR functional genomics and biomarker studies
CRISPR screens and targeted knockouts can test causal roles of FAD biosynthetic genes in ferroptosis, cancer and metabolic phenotypes. Biomarker-oriented studies, such as plasma PPP2R5C for Alzheimer's disease, illustrate how metabolic pathway candidates can be evaluated in clinical research.
How CRISPR Can Be Used to Study GO:0006747 FAD biosynthetic process
Knockout
CRISPR knockout of FAD biosynthetic genes such as FLAD1 or RFK can reveal whether the pathway is required for flavoprotein activity, ferroptosis resistance and metabolic flux. Knockout models are also useful for testing dependencies in cancer cell lines and for identifying rescue by exogenous FAD.
Point Mutation
Point-mutation knock-in of catalytic residues in FAD synthetase or riboflavin kinase allows separation of enzymatic activity from scaffolding functions. Similarly, point mutations in flavoenzymes such as ACOX1 can test allosteric regulation by ATP.
Knock-in
Tagged knock-in of FAD biosynthetic enzymes enables localization, interaction and dynamic studies in native chromatin context. Knock-in of disease-associated variants can model flavoprotein dysfunction and cofactor handling.
Overexpression
Overexpression of FAD biosynthetic genes or downstream effectors such as FSP1 can test sufficiency for ferroptosis suppression and metabolic remodeling. Overexpression models also help determine whether increased FAD flux enhances flavoprotein-dependent phenotypes.
How EDITGENE Supports FAD biosynthetic process Research
Researchers studying FAD biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in cofactor supply, flavoprotein activity or disease phenotypes. EDITGENE provides CRISPR-based cell model services that allow precise, reproducible testing of these hypotheses in relevant cellular backgrounds.
Contact EDITGENE today to design your custom CRISPR model for FAD biosynthetic process research.
Frequently Asked Questions About FAD biosynthetic process
What is FAD biosynthetic process (GO:0006747)?
It is the biological process that produces FAD, the oxidized form of flavin adenine dinucleotide, through reactions that convert riboflavin to FMN and then to FAD.
What genes are involved in FAD biosynthetic process?
Key genes include riboflavin transporters (SLC52A1-3), riboflavin kinase (RFK) and FAD synthetase (FLAD1), with downstream flavoproteins such as FSP1 and ACOX1 as functional readouts.
Why is FAD biosynthesis important for cells?
FAD is the cofactor for a large flavoproteome, so its biosynthesis supports mitochondrial metabolism, redox balance and cell survival pathways.
How is FAD biosynthesis linked to ferroptosis?
Vitamin B2 metabolism promotes FSP1 stability to prevent ferroptosis, so FAD availability directly influences lipid peroxidation defense.
Can FAD act as a signaling molecule?
Yes, the microbial metabolite FAD can mobilize adipocyte lipid remodeling and enhance cancer immunotherapy efficacy.
What diseases are associated with FAD biosynthetic process?
Flavoprotein dysfunction is linked to metabolic disorders, ferroptosis-related cancer biology and neurodegeneration research.
How do researchers study FAD biosynthesis?
They use metabolomics, enzyme activity assays, CRISPR screens, structural biology and single-molecule enzymology.
What CRISPR models are useful for FAD pathway research?
Knockout, point-mutation, knock-in, tagged knock-in and overexpression models can test causality and sufficiency of FAD biosynthetic genes.
Is FAD biosynthesis relevant to cancer immunotherapy?
Yes, FAD produced by microbes can remodel adipocyte lipids and enhance immunotherapy efficacy, linking FAD biology to anti-tumor immunity.
How does ATP regulate flavoenzymes?
ATP can allosterically regulate flavoenzymes such as acyl-CoA oxidase, tuning their catalytic activity.
Conclusion
GO:0006747 (FAD biosynthetic process) is a central metabolic pathway that supplies the FAD cofactor required by the human flavoproteome and by flavin-dependent enzymes across biology. Its outputs extend beyond cofactor supply to influence ferroptosis, lipid remodeling and immunotherapy response, making it a high-value process for mechanistic and translational research. CRISPR-based knockout, point-mutation, knock-in and overexpression models provide the causal tools needed to dissect this pathway in disease-relevant contexts.
References
- 1. Tong T et al.. 2026. Microbial metabolite FAD mobilizes adipocyte lipid remodeling to enhance cancer immunotherapy efficacy.. Cell Metab 38(3):565-581.e5 PMID: 41570815
- 2. Lienhart WD et al.. 2013. The human flavoproteome.. Arch Biochem Biophys 535(2):150-62 PMID: 23500531
- 3. Perez DH et al.. 2025. ATP allosterically regulates an acyl-CoA oxidase.. Nat Commun 16(1):7318 PMID: 40781076
- 4. Ramos Figueroa J et al.. 2024. Unexpected Transformations during Pyrroloiminoquinone Biosynthesis.. J Am Chem Soc 146(20):14235-14245 PMID: 38719200
- 5. Deol KK et al.. 2026. Vitamin B2 metabolism promotes FSP1 stability to prevent ferroptosis.. Nat Struct Mol Biol 33(3):525-536 PMID: 41826758
- 7. Lu HP et al.. 1998. Single-molecule enzymatic dynamics.. Science 282(5395):1877-82 PMID: 9836635
- 8. Luo S et al.. 2026. Neuronal PPP2R5C in plasma is a potential biomarker for early diagnosis of Alzheimer's disease.. Cell Rep Med 7(3):102631 PMID: 41720088
